National Health Investors Inc (NHI) stock
Close on Nov 18, 2026Market cap $3.07BP/E 18.0Yield 5.57%
Earnings
National Health Investors's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of National Health Investors's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026after the close | – | – | $11.47 | $1.12 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 10, 2026during market hours | $121.32M | +33.8% | $1.15 | $1.19 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 4, 2026during market hours | $115.13M | +28.9% | $0.82 | $1.23 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026during market hours | $105.82M | +23.4% | $0.80 | $1.22 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025during market hours | $89.85M | +8.3% | $0.69 | $1.32 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025during market hours | $90.66M | – | $0.79 | $1.22 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 5, 2025during market hours | $89.30M | +9.5% | $0.74 | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 25, 2025during market hours | $85.75M | – | $0.95 | $1.12 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 5, 2024during market hours | $82.94M | +3.5% | $0.65 | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024during market hours | – | – | $0.81 | $1.18 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 6, 2024during market hours | $81.51M | -1.1% | $0.71 | $1.12 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 20, 2024during market hours | – | – | $0.74 | $1.09 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023during market hours | $80.11M | – | $0.68 | $1.08 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023during market hours | $77.88M | +30.0% | $0.92 | $1.06 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023during market hours | $82.39M | – | $0.79 | $1.11 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 21, 2023during market hours | $70.67M | +1.4% | $0.04 | $0.85 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022during market hours | – | – | $0.78 | $1.06 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022during market hours | $59.90M | – | $0.47 | $1.26 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022during market hours | – | – | $0.18 | $1.10 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 22, 2022during market hours | $69.67M | – | $0.14 | $1.06 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 8, 2021during market hours | $73.83M | – | $0.67 | $1.15 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 9, 2021during market hours | – | – | – | – | Release |
| Q1 FY2021ended Mar 31, 2021 | May 10, 2021during market hours | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 22, 2021during market hours | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 9, 2020during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
National Health Investors's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Same Store SHOP NOI growth on 26 propertiesnon-GAAP | Q4 FY2026 | 0% – +1% | – | New | Nov 9, 2026 |
| Same Store SHOP NOI growth | FY2026 | +1% – +3% | +7% – +8% | Lowered | Aug 10, 2026 |
| Same Store SHOP NOI growth on 15 propertiesnon-GAAP | FY2026 | +1% – +3% | – | New | Nov 9, 2026 |
| Total SHOP NOI on 42 properties, before the assumption for unidentified new SHOP investmentsnon-GAAP | FY2026 | $44.10M – $45.10M | – | New | May 4, 2026 |
| NAREIT FFO per diluted sharenon-GAAP | FY2026 | $4.74 – $4.79 | $4.74 – $4.79 | Reaffirmed | Aug 10, 2026 |
| FAD attributable to common stockholdersnon-GAAP | FY2026 | $240.60M – $243.70M | – | New | May 4, 2026 |
| FAD attributable to common stockholdersnon-GAAP | FY2026 | $240.60M – $243.70M | $248.90M – $251.40M | Raised | Aug 10, 2026 |
| NAREIT FFO attributable to common stockholdersnon-GAAP | FY2026 | $232.30M – $234.90M | $232.30M – $234.90M | Reaffirmed | Aug 10, 2026 |
| NAREIT FFO per diluted sharenon-GAAP | FY2026 | $4.74 – $4.79 | $4.94 – $4.99 | Lowered | May 4, 2026 |
| Net income attributable to common stockholdersGAAP | FY2026 | $703.00M – $705.20M | $703.00M – $705.20M | Reaffirmed | Aug 10, 2026 |
| Normalized FADnon-GAAP | FY2026 | $240.60M – $243.70M | $248.90M – $251.40M | Lowered | May 4, 2026 |
| Normalized FFO attributable to common stockholdersnon-GAAP | FY2026 | $232.30M – $234.90M | $232.30M – $234.90M | Reaffirmed | Aug 10, 2026 |
| Same Store SHOP NOI growth on 15 propertiesnon-GAAP | FY2026 | +1% – +3% | – | New | May 4, 2026 |
| Total SHOP NOI | FY2026 | $44.10M – $45.10M | – | New | Aug 10, 2026 |
| total SHOP NOI growth | FY2026 | +105% – +109% | – | New | Feb 26, 2026 |
| Total SHOP NOI on 48 propertiesnon-GAAP | FY2026 | $43.80M – $44.30M | – | New | Nov 9, 2026 |
Guidance vs results
The last range National Health Investors gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2025 | Revenue | $8.80M | $89.85M | Above range |
Guidance history
Every forecast National Health Investors put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 9, 2026 | Same Store SHOP NOI growth on 26 properties | Q4 FY2026 | 0% – +1% | New |
| Nov 9, 2026 | Same Store SHOP NOI growth on 15 properties | FY2026 | +1% – +3% | New |
| Nov 9, 2026 | Total SHOP NOI on 48 properties | FY2026 | $43.80M – $44.30M | New |
| Aug 10, 2026 | Same Store SHOP NOI growth | FY2026 | +1% – +3% | Lowered |
| Aug 10, 2026 | NAREIT FFO per diluted share | FY2026 | $4.74 – $4.79 | Reaffirmed |
| Aug 10, 2026 | Normalized FFO per diluted share | FY2026 | $4.74 – $4.79 | Reaffirmed |
| Aug 10, 2026 | Total SHOP NOI | FY2026 | $44.10M – $45.10M | New |
| Aug 10, 2026 | Net income attributable to common stockholders | FY2026 | $703.00M – $705.20M | Reaffirmed |
| Aug 10, 2026 | NAREIT FFO attributable to common stockholders | FY2026 | $232.30M – $234.90M | Reaffirmed |
| Aug 10, 2026 | Normalized FFO attributable to common stockholders | FY2026 | $232.30M – $234.90M | Reaffirmed |
| Aug 10, 2026 | FAD attributable to common stockholders | FY2026 | $240.60M – $243.70M | Raised |
| May 4, 2026 | Normalized FFO per diluted share | FY2026 | $4.74 – $4.79 | Lowered |
| May 4, 2026 | FAD attributable to common stockholders | FY2026 | $240.60M – $243.70M | New |
| May 4, 2026 | Total SHOP NOI on 42 properties, before the assumption for unidentified new SHOP investments | FY2026 | $44.10M – $45.10M | New |
| May 4, 2026 | Same Store SHOP NOI growth on 15 properties | FY2026 | +1% – +3% | New |
| May 4, 2026 | Net income attributable to common stockholders | FY2026 | $703.00M – $705.20M | Raised |
| May 4, 2026 | Normalized FAD | FY2026 | $240.60M – $243.70M | Lowered |
| May 4, 2026 | NAREIT FFO attributable to common stockholders | FY2026 | $232.30M – $234.90M | Lowered |
| May 4, 2026 | Normalized FFO attributable to common stockholders | FY2026 | $232.30M – $234.90M | Reaffirmed |
| May 4, 2026 | NAREIT FFO per diluted share | FY2026 | $4.74 – $4.79 | Lowered |
| Feb 26, 2026 | Same Store SHOP NOI growth | FY2026 | +7% – +8% | New |
| Feb 26, 2026 | Normalized FFO per diluted share | FY2026 | $4.94 – $4.99 | New |
| Feb 26, 2026 | total SHOP NOI growth | FY2026 | +105% – +109% | New |
| Feb 26, 2026 | Net income attributable to common stockholders | FY2026 | $180.10M – $182.40M | New |
| Feb 26, 2026 | Normalized FAD | FY2026 | $248.90M – $251.40M | New |
| Feb 26, 2026 | NAREIT FFO attributable to common stockholders | FY2026 | $241.90M – $244.20M | Lowered |
| Feb 26, 2026 | Normalized FFO attributable to common stockholders | FY2026 | $241.90M – $244.20M | Reaffirmed |
| Feb 26, 2026 | FAD attributable to common stockholders | FY2026 | $248.90M – $251.40M | Raised |
| Feb 26, 2026 | NAREIT FFO per diluted share | FY2026 | $4.94 – $4.99 | New |
| Nov 6, 2025 | Normalized FFO per diluted share | FY2025 | $4.88 – $4.91 | New |
| Nov 6, 2025 | Same Store SHOP NOI growth | FY2025 | +7% – +9% | New |
| Nov 6, 2025 | Net income attributable to common stockholders | FY2025 | $139.10M – $140.60M | New |
| Nov 6, 2025 | Normalized FAD | FY2025 | $231.70M – $233.50M | New |
| Nov 6, 2025 | NAREIT FFO attributable to common stockholders | FY2025 | $217.10M – $218.60M | Lowered |
| Nov 6, 2025 | Normalized FFO attributable to common stockholders | FY2025 | $229.50M – $231.00M | Raised |
| Nov 6, 2025 | SHOP conversion NOI plus new SHOP investment NOI | FY2025 | $5.80M – $6.00M | Lowered |
| Nov 6, 2025 | NAREIT FFO per diluted share | FY2025 | $4.62 – $4.65 | New |
| Aug 6, 2025 | Additional SHOP conversion routine capital expenditures | FY2025 | $500.00K | New |
| Aug 6, 2025 | Normalized FFO per diluted common share | FY2025 | $4.78 – $4.82 | Raised |
| Aug 6, 2025 | SHOP conversion NOI | FY2025 | $3.60M – $3.70M | New |
| Aug 6, 2025 | NAREIT FFO attributable to common stockholders | FY2025 | $209.60M – $211.70M | Lowered |
| Aug 6, 2025 | Normalized FAD | FY2025 | $227.90M – $229.80M | Raised |
| Aug 6, 2025 | Net income attributable to common stockholders | FY2025 | $132.90M – $135.00M | Lowered |
| Aug 6, 2025 | unidentified new investments | FY2025 | $105.00M | Lowered |
| Aug 6, 2025 | Same-store (15) SHOP NOI growth | FY2025 | +13% – +16% | Raised |
| Aug 6, 2025 | NAREIT FFO per diluted common share | FY2025 | $4.46 – $4.50 | Lowered |
| Aug 6, 2025 | Normalized FFO attributable to common stockholders | FY2025 | $224.80M – $226.40M | Raised |
| Aug 6, 2025 | initial average yield | FY2025 | 8.1% | New |
| Aug 6, 2025 | reduction in rental income | Q3 FY2025 | $8.80M | New |
| Aug 6, 2025 | lower expected Discovery cash rent for the year, net of deferred rent recoveries | FY2025 | $800.00K | New |
| May 5, 2025 | NAREIT FFO attributable to common stockholders | FY2025 | $218.30M – $220.70M | Lowered |
| May 5, 2025 | NFFO per diluted common share | FY2025 | $4.68 – $4.73 | Raised |
| May 5, 2025 | NAREIT FFO per diluted common share | FY2025 | $4.64 – $4.70 | Raised |
| May 5, 2025 | FAD attributable to common stockholders | FY2025 | $223.80M – $226.40M | Raised |
| May 5, 2025 | Normalized FFO (NFFO) attributable to common stockholders | FY2025 | $220.10M – $222.50M | Raised |
| May 5, 2025 | Net income attributable to common stockholders | FY2025 | $143.70M – $146.10M | New |
| May 5, 2025 | SHOP NOI growth | FY2025 | +12% – +15% | New |
| Feb 25, 2025 | Normalized FFO per diluted common share | FY2025 | $4.59 – $4.66 | New |
| Feb 25, 2025 | Normalized FAD | FY2025 | $219.80M – $223.60M | Reaffirmed |
| Feb 25, 2025 | FAD attributable to common stockholders | FY2025 | $219.80M – $223.60M | Raised |
| Feb 25, 2025 | Normalized FFO (NFFO) attributable to common stockholders | FY2025 | $214.70M – $218.10M | Reaffirmed |
| Feb 25, 2025 | NAREIT FFO attributable to common stockholders | FY2025 | $214.70M – $218.10M | New |
| Feb 25, 2025 | Net income attributable to common stockholders | FY2025 | $141.60M – $145.00M | New |
| Feb 25, 2025 | SHOP NOI growth | FY2025 | +12% – +15% | New |
| Feb 25, 2025 | NAREIT FFO per diluted common share | FY2025 | $4.59 – $4.66 | New |
| Nov 5, 2024 | FAD attributable to common stockholders | FY2024 | $201.80M – $202.50M | New |
| Nov 5, 2024 | SHOP NOI growth | FY2024 | +28% – +30% | New |
| Nov 5, 2024 | Net income attributable to common stockholders | FY2024 | $130.30M – $131.00M | New |
| Nov 5, 2024 | NAREIT FFO attributable to common stockholders | FY2024 | $193.80M – $194.40M | Lowered |
| Nov 5, 2024 | Normalized FFO (NFFO) attributable to common stockholders | FY2024 | $195.30M – $195.90M | Raised |
| Nov 5, 2024 | NAREIT FFO per diluted common share | FY2024 | $4.39 – $4.41 | Lowered |
| Nov 5, 2024 | NFFO per diluted common share | FY2024 | $4.43 – $4.44 | Raised |
| Aug 6, 2024 | Normalized FFO per diluted common share | FY2024 | $4.52 – $4.56 | Raised |
| Aug 6, 2024 | Normalized FAD | FY2024 | $200.10M – $201.80M | Raised |
| Aug 6, 2024 | NAREIT FFO per diluted common share | FY2024 | $4.50 – $4.54 | Raised |
| May 6, 2024 | Normalized FFO per diluted common share | FY2024 | $4.37 – $4.43 | Raised |
| May 6, 2024 | SHOP NOI growth | FY2024 | +25% – +30% | Reaffirmed |
| May 6, 2024 | Normalized FAD | FY2024 | $196.70M – $199.20M | Raised |
| May 6, 2024 | NAREIT FFO per diluted common share | FY2024 | $4.36 – $4.41 | Raised |
| Feb 20, 2024 | Normalized FFO per diluted common share | FY2024 | $4.31 – $4.37 | New |
| Feb 20, 2024 | SHOP NOI growth | FY2024 | +25% – +30% | New |
| Feb 20, 2024 | Normalized FAD | FY2024 | $191.30M – $194.10M | New |
| Feb 20, 2024 | NAREIT FFO per diluted common share | FY2024 | $4.31 – $4.37 | New |
| Nov 7, 2023 | Normalized FFO per share | FY2023 | $4.28 – $4.31 | Lowered |
| Nov 7, 2023 | Normalized FAD | FY2023 | $186.00M – $187.60M | Raised |
| Aug 8, 2023 | Normalized FFO per share | FY2023 | $4.31 – $4.35 | Lowered |
| Aug 8, 2023 | Normalized FAD | FY2023 | $185.00M – $186.80M | Lowered |
| May 9, 2023 | Normalized FFO per share | FY2023 | $4.37 – $4.42 | Raised |
| May 9, 2023 | Normalized FAD | FY2023 | $186.30M – $188.90M | New |
| Feb 21, 2023 | NFFO per diluted common share | FY2023 | $4.24 – $4.30 | New |
| Aug 8, 2022 | Normalized FFO per diluted common share | FY2022 | $4.48 – $4.53 | Raised |
| Aug 8, 2022 | Weighted average diluted common shares | FY2022 | 45.2 | Lowered |
| Aug 8, 2022 | Normalized Funds Available for Distribution | FY2022 | $200.20M – $203.00M | Lowered |
| Aug 8, 2022 | NAREIT FFO per diluted common share | FY2022 | $3.86 – $3.92 | Lowered |
| May 9, 2022 | Normalized FFO per diluted common share | FY2022 | $4.38 – $4.48 | New |
| May 9, 2022 | Weighted average diluted common shares | FY2022 | 45.9 | New |
| May 9, 2022 | Funds Available for Distribution | FY2022 | $201.80M – $206.40M | New |
| May 9, 2022 | NAREIT FFO per diluted common share | FY2022 | $4.32 – $4.42 | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases National Health Investors filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Results
- Update
- Update
- Update
- Results
- Update
- Update
- Update
- Results
- Update
- Update
- Update
See a number that looks wrong?